Metformin/sitagliptin and effect on renal function in patients with type 2 diabetes mellitus
DOI:
https://doi.org/10.51481/amc.v66i3.1389Keywords:
Diabetes mellitus type 2, Glycemic control, Kidney Function Tests, Metformin, SitagliptinAbstract
Aim: To determine the effect of metformin-sitagliptin on glycemic control and the preservation of renal function in patients with type 2 diabetes mellitus.
Methods: This quasi-experimental study was conducted from September 2021 to July 2022, involving patients with type 2 diabetes who had HbA1c levels ≥ 7% and were treated solely with metformin (1700 mg/24 h). In the second consultation, a combination of metformin-sitagliptin 850mg/50mg was initiated orally, twice a day. Measurements were taken for Body Mass Index, systolic blood pressure, diastolic blood pressure, glycosylated hemoglobin, and serum concentrations of glucose, total cholesterol, triglycerides, low-density lipoproteins, high-density lipoproteins, and Glomerular Filtration Rate at baseline and 6 months post-treatment.
Results: 139 patients were recruited (50 males, 89 females), the median age in males was 58 (26-77) years; in females were 55 (30-79) years. Initial median %HbA1c: 8.1 (7.47-9.38); Initial median Glomerular Filtration Rate: 100 (85-110) mL/min/m2. After 6 months of metformin-sitagliptin treatment, glucose decreased in males (Δ-26.23%; p= 0.0001) and in females (Δ-19.49%; p= 0.0001). 28.6% of males and 42.9% of females achieved HbA1c <7%. Renal function was preserved post-treatment (Δ+3%).
Conclusion: The use of metformin-sitagliptin for 6 months improved HbA1c levels, total cholesterol, and triglycerides while preserving renal function in patients with DM2. These results suggest that the combination of sitagliptin with metformin could be a useful strategy for managing patients with DM2. New studies and clinical guidelines for managing patients with type 2 diabetes (DM2) recommend the use of sitagliptin; therefore, further research is needed to evaluate its long-term impact on hyperglycemia management in DM2 and on renal function.
Downloads
References
1. Muñoz HA, Lúquez AJ, Gómez AJ. Fisiopatología de la hepatitis C y diabetes mellitus. Hacia la cura de dos epidemias en el siglo XXI. Rev Colomb Gastroenterol. 2019;34:277–87. doi.org/10.22516/25007440.
2. Flores-Hernández S, Acosta-Ruiz O, Hernández-Serrato MI, Delgado-Rodríguez S, Reyes-Morales H. Calidad de la atención en diabetes tipo 2, avances y retos de 2012 a 2018-19 para el sistema de salud de México. Salud Publica Mex. 2020;62:618-626. doi.org/10.21149/11876
3. Basto-Abreu A, López-Olmedo N, Rojas-Martínez R, Aguilar-Salinas CA, Moreno-Banda GL, Carnalla M, et al. Prevalencia de prediabetes y diabetes en México: Ensanut 2022. Salud Publica Mex. 2023;65: S163-S168. doi.org/10.21149/14832
4. American Diabetes Association. Standards of medical care in diabetes—2021. Diabetes Care 2021; 44:S15-S73. doi.org/10.2337/dc21-S002
5. Costa Gil JE, Spinedi E. La tormentosa relación entre las grasas y el desarrollo de la diabetes mellitus de tipo 2: actualizado. Parte 1. Rev Argent Endocrinol Metab. 2017;54:109-123. doi.org/10.1016/j.raem.2017.06.001
6. Ceriello A, Prattichizzo F. Variability of risk factors and diabetes complications. Cardiovasc Diabetol. 2021;20:101. doi.org/10.1186/s12933-021-01289-4.
7. Jing X, Chen J, Dong Y, Han D, Zhao H, Wang X, et al. Related factors of quality of life of type 2 diabetes patients: a systematic review and meta-analysis. Health Qual Life Outcomes. 2018;16:189. doi.org/10.1186/s12955-018-1021-9.
8. Raveendran AV, Chacko EC, Pappachan JM. Non-pharmacological treatment options in the management of diabetes mellitus. Eur Endocrinol. 2018;14:31–9. doi.org/ 10.17925/EE.2018.14.2.31
9. Xu X, Bi Y. New way, new recommendation: Individualized treatment of novel antidiabetic drugs for people living with type 2 diabetes based on the cardiorenal risks. J Evid Based Med. 2021;14:262-264. doi.org/10.1111/jebm.12452.
10. LaMoia TE, Shulman GI. Cellular and Molecular Mechanisms of Metformin Action. Endocr Rev. 2021;42:77-96. doi.org/10.1210/endrev/bnaa023.
11. Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol. 2019;15:569-589. doi.org/10.1038/s41574-019-0242-2.
12. Flory J, Lipska K. Metformin in 2019. JAMA. 2019;321:1926-1927. doi.org/10.1001/jama.2019.3805.
13. Mbara KC, Mofo Mato PE, Driver C, Nzuza S, Mkhombo NT, Gcwensa SK, et al. Metformin turns 62 in pharmacotherapy: Emergence of non-glycaemic effects and potential novel therapeutic applications. Eur J Pharmacol. 2021;898:173934. doi.org/10.1016/j.ejphar.2021.173934.
14. Bharath LP, Nikolajczyk BS. The intersection of metformin and inflammation. Am J Physiol Cell Physiol. 2021;320:C873-C879. doi.org/10.1152/ajpcell.00604.2020.
15. Kawanami D, Takashi Y, Tanabe M. Significance of Metformin Use in Diabetic Kidney Disease. Int J Mol Sci. 2020;21:4239. doi.org/10.3390/ijms21124239.
16. Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, PIONEER 3 Investigators, et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019;321:1466-1480. doi.org/10.1001/jama.2019.2942.
17. GRADE Study Research Group, Nathan DM, Lachin JM, Bebu I, Burch HB, Buse JB, et al. Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. N Engl J Med.;387:1075-1088. doi.org/10.1056/NEJMoa2200436.
18. Bailey CJ. Metformin: historical overview. Diabetología 2017; 60(9): 1566–1576. doi.org/10.1007/s00125-017-4318-z.
19. Rodríguez N, Cuautle P, Molina J. Hipoglucemiantes orales para el tratamiento de diabetes mellitus tipo 2: uso y regulación en México. Rev Hosp Jua Mex. 2017; 84: 203-211.
20. Martínez-Castelao A, Górriz JL, Ortiz A, Navarro-González JF. Guía ERBP sobre la diabetes en la enfermedad renal crónica estadio 3B o mayor: ¿metformina para todos?. Nefrología. 2017; 37:567–571. doi.org/10.1016/j.nefro.2017.06.001
21. Manterola C, Otzen T. Estudios Experimentales 2ª Parte. Estudios Cuasiexperimentales. Int. J. Morphol. 2015;33:382-387. doi.org/10.4067/S0717-95022015000100060
22. Xu B, Shen T, Chen L, Xia J, Zhang C, Wang H, et al. The effect of sitagliptin on lipid metabolism of fatty liver mice and related mechanisms. Med Sci Monit 2017; 23: 1363–1370. doi.org/10.12659/msm.900033
23. American Diabetes Association Professional Practice Committee; 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024. Diabetes Care 1 January 2024; 47 (Supplement 1): S158–S178. doi.org/10.2337/dc24-S009
24. Oujo B, Muñoz-Félix JM, Arévalo M, Núñez-Gómez E, Pérez-Roque L, Pericacho M, et al: L-Endoglin overexpression increases renal fibrosis after unilateral ureteral obstruction. PLoS One. 2014; 9: e110365. doi.org/10.1371/journal.pone.0110365
25. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016; 375: 323–334. doi.org/10.1056/NEJMoa1515920
26. Hematyar J, Rashidi H, Zakerkish M, Payami SP, Ghaderian SB. Effect of Sitagliptin Versus Glibenclamide on Glycemic Markers, Lipid Profile Inflammatory and Oxidative Stress Factors in Type 2 Diabetes Patients: a Double-Blinded Randomized Controlled Trial. Maedica (Bucur). 2022;17:762-770. doi.org/10.26574/maedica.2022.17.4.762
27. Tanimura-Inagaki K, Nagao M, Harada T, Sugihara H, Moritani S, Sasaki J. Sitagliptin improves plasma apolipoprotein profile in type 2 diabetes: A randomized clinical trial of sitagliptin effect on lipid and glucose metabolism (SLIM) study. Diabetes Res Clin Pract. 2020;162:108119. doi.org/10.1016/j.diabres.2020.108119
28. Tomonaga O, Sakura H, Hashimoto N, Sasamoto K, Ohashi H, Hasumi S, et al. Renal Function During an Open-Label Prospective Observational Trial of Sitagliptin in Patients With Diabetes: A Sub-Analysis of the JAMP Study. J Clin Med Res. 2018;10:32-40. doi.org/10.14740/jocmr3225w
29. Calderón Montero A. Evidencias de los iSGLT2 en el tratamiento de la enfermedad renal crónica. Medicina de Familia (Semergen). 2023;49(S1):102019. doi.org/10.1016/j.semerg.2023.102019
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2025 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
